{"title":"达比加群作为阿斯利康SARS-Cov-2疫苗诱导的血栓性免疫性血小板减少症的替代疗法","authors":"J. J. Cerezo-Manchado, T. I. Hernández","doi":"10.15406/jccr.2021.14.00531","DOIUrl":null,"url":null,"abstract":"Reviewing the treatment alternatives for thormbotic thrombocytopenia induced by vaccine (TTIV) after receiving a dose of ChAdOx1 nCov-19 vaccine (AstraZeneca) we observe that dabigatran should be an alternative to be considered since it has several strength points that may be useful in this pathology: Specific antidote, low level of interactions with others drugs and effectiveness in thrombotic events.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"6 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dabigatran as alternative therapy in prothrombotic immune thrombocytopenia induced by the AstraZeneca SARS-Cov-2 vaccine \",\"authors\":\"J. J. Cerezo-Manchado, T. I. Hernández\",\"doi\":\"10.15406/jccr.2021.14.00531\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Reviewing the treatment alternatives for thormbotic thrombocytopenia induced by vaccine (TTIV) after receiving a dose of ChAdOx1 nCov-19 vaccine (AstraZeneca) we observe that dabigatran should be an alternative to be considered since it has several strength points that may be useful in this pathology: Specific antidote, low level of interactions with others drugs and effectiveness in thrombotic events.\",\"PeriodicalId\":15200,\"journal\":{\"name\":\"Journal of Cardiology & Current Research\",\"volume\":\"6 2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiology & Current Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/jccr.2021.14.00531\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiology & Current Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/jccr.2021.14.00531","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dabigatran as alternative therapy in prothrombotic immune thrombocytopenia induced by the AstraZeneca SARS-Cov-2 vaccine
Reviewing the treatment alternatives for thormbotic thrombocytopenia induced by vaccine (TTIV) after receiving a dose of ChAdOx1 nCov-19 vaccine (AstraZeneca) we observe that dabigatran should be an alternative to be considered since it has several strength points that may be useful in this pathology: Specific antidote, low level of interactions with others drugs and effectiveness in thrombotic events.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
